AbbVie annual operating income
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
AbbVie Operating Income Growth & History (ABBV)
AbbVie's operating income was $15.07B for fiscal 2025.
View full AbbVie company overviewAbbVie annual operating income history
| Fiscal year | Period ended | Operating income | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $15.07B | $5.94B | +64.99% |
| 2024 | 2024-12-31 | $9.14B | −$3.62B | −28.38% |
| 2023 | 2023-12-31 | $12.76B | −$5.36B | −29.59% |
| 2022 | 2022-12-31 | $18.12B | $193.0M | +1.08% |
| 2021 | 2021-12-31 | $17.92B | $6.56B | +57.74% |
| 2020 | 2020-12-31 | $11.36B | −$1.62B | −12.48% |
| 2019 | 2019-12-31 | $12.98B | $6.60B | +103.40% |
| 2018 | 2018-12-31 | $6.38B | −$3.16B | −33.13% |
| 2017 | 2017-12-31 | $9.54B | $205.0M | +2.19% |
| 2016 | 2016-12-31 | $9.34B | $1.80B | +23.92% |
| 2015 | 2015-12-31 | $7.54B | $4.13B | +120.96% |
| 2014 | 2014-12-31 | $3.41B | −$2.25B | −39.78% |
| 2013 | 2013-12-31 | $5.66B | −$153.0M | −2.63% |
| 2012 | 2012-12-31 | $5.82B | $2.20B | +60.69% |
| 2011 | 2011-12-31 | $3.62B | — | — |
AbbVie quarterly operating income
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating income | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $6.43B | $1.54B | +31.43% |
| Q1 2026 | 2026-03-31 | $3.99B | $257.0M | +6.88% |
| Q4 2025 | 2025-12-31 | $4.54B | $6.03B | — |
| Q3 2025 | 2025-09-30 | $1.90B | −$1.93B | −50.30% |
| Q2 2025 | 2025-06-30 | $4.89B | $896.0M | +22.41% |
| Q1 2025 | 2025-03-31 | $3.73B | $935.0M | +33.42% |
| Q4 2024 | 2024-12-31 | −$1.49B | −$4.68B | — |
| Q3 2024 | 2024-09-30 | $3.83B | $1.55B | +67.95% |
| Q2 2024 | 2024-06-30 | $4.00B | −$515.0M | −11.41% |
| Q1 2024 | 2024-03-31 | $2.80B | $30.0M | +1.08% |
| Q4 2023 | 2023-12-31 | $3.19B | −$2.31B | −41.93% |
| Q3 2023 | 2023-09-30 | $2.28B | −$2.32B | −50.45% |
| Q2 2023 | 2023-06-30 | $4.51B | $1.22B | +36.97% |
| Q1 2023 | 2023-03-31 | $2.77B | −$1.95B | −41.32% |
| Q4 2022 | 2022-12-31 | $5.50B | $428.0M | +8.44% |
| Q3 2022 | 2022-09-30 | $4.60B | $297.0M | +6.90% |
| Q2 2022 | 2022-06-30 | $3.29B | −$1.15B | −25.80% |
| Q1 2022 | 2022-03-31 | $4.72B | $614.0M | +14.96% |
| Q4 2021 | 2021-12-31 | $5.07B | $1.32B | +35.20% |
| Q3 2021 | 2021-09-30 | $4.31B | $1.05B | +32.29% |
| Q2 2021 | 2021-06-30 | $4.44B | $3.69B | +490.56% |
| Q1 2021 | 2021-03-31 | $4.10B | $500.0M | +13.88% |
| Q4 2020 | 2020-12-31 | $3.75B | −$203.0M | −5.13% |
| Q3 2020 | 2020-09-30 | $3.25B | $638.0M | +24.38% |
| Q2 2020 | 2020-06-30 | $752.0M | −$2.65B | −77.88% |
| Q1 2020 | 2020-03-31 | $3.60B | $593.0M | +19.70% |
| Q4 2019 | 2019-12-31 | $3.96B | $6.40B | — |
| Q3 2019 | 2019-09-30 | $2.62B | −$542.0M | −17.16% |
| Q2 2019 | 2019-06-30 | $3.40B | $638.0M | +23.10% |
| Q1 2019 | 2019-03-31 | $3.01B | $107.0M | +3.69% |
| Q4 2018 | 2018-12-31 | −$2.44B | −$4.22B | — |
| Q3 2018 | 2018-09-30 | $3.16B | $465.0M | +17.26% |
| Q2 2018 | 2018-06-30 | $2.76B | $100.0M | +3.76% |
| Q1 2018 | 2018-03-31 | $2.90B | $496.0M | +20.61% |
| Q4 2017 | 2017-12-31 | $1.78B | −$532.0M | −22.99% |
| Q3 2017 | 2017-09-30 | $2.69B | $333.0M | +14.10% |
| Q2 2017 | 2017-06-30 | $2.66B | $275.0M | +11.52% |
| Q1 2017 | 2017-03-31 | $2.41B | $129.0M | +5.66% |
| Q4 2016 | 2016-12-31 | $2.31B | $201.0M | +9.51% |
| Q3 2016 | 2016-09-30 | $2.36B | $476.0M | +25.25% |
| Q2 2016 | 2016-06-30 | $2.39B | $535.0M | +28.89% |
| Q1 2016 | 2016-03-31 | $2.28B | $591.0M | +35.03% |
| Q4 2015 | 2015-12-31 | $2.11B | $2.53B | — |
| Q3 2015 | 2015-09-30 | $1.89B | $925.0M | +96.35% |
| Q2 2015 | 2015-06-30 | $1.85B | $337.0M | +22.24% |
| Q1 2015 | 2015-03-31 | $1.69B | $336.0M | +24.87% |
| Q4 2014 | 2014-12-31 | −$415.0M | −$1.95B | — |
| Q3 2014 | 2014-09-30 | $960.0M | −$411.0M | −29.98% |
| Q2 2014 | 2014-06-30 | $1.51B | $62.0M | +4.27% |
| Q1 2014 | 2014-03-31 | $1.35B | $46.0M | +3.52% |
| Q4 2013 | 2013-12-31 | $1.53B | −$286.0M | −15.71% |
| Q3 2013 | 2013-09-30 | $1.37B | −$225.0M | −14.10% |
| Q2 2013 | 2013-06-30 | $1.45B | $31.0M | +2.18% |
| Q1 2013 | 2013-03-31 | $1.30B | $327.0M | +33.44% |
| Q4 2012 | 2012-12-31 | $1.82B | — | — |
| Q3 2012 | 2012-09-30 | $1.60B | — | — |
| Q2 2012 | 2012-06-30 | $1.42B | — | — |
| Q1 2012 | 2012-03-31 | $978.0M | — | — |
AbbVie operating income trends
Over the last five fiscal years, AbbVie's operating income increased from $11.36B to $15.07B, a change of $3.71B. The latest reported quarter, Q2 2026, shows $6.43B.
About the metric
What operating income means
Operating income is the profit or loss a company generates from its core business after cost of revenue and operating expenses, but before non-operating items such as interest and income taxes.
Calculation and source
SEC-reported operating income
TickerStat standardizes operating income reported in company SEC filings for aligned fiscal periods. It is not adjusted EBIT, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review AbbVie source filings ↗Community posts
FDA clears at-home Skyrizi induction for Crohn’s disease
AbbVie ($ABBV) received FDA approval for subcutaneous induction dosing of Skyrizi in adults with moderately to severely active Crohn’s disease. Patients can now begin treatment at home using an on-body injector, extending that delivery opti ...
AbbVie meets pivotal hidradenitis endpoint with lutikizumab
AbbVie ($ABBV) reported that lutikizumab met the main endpoint and all eight ranked secondary endpoints in the Phase 3 INTREPID trial for moderate to severe hidradenitis suppurativa. At week 16, 31.4% of treated patients achieved HiSCR75, c ...
AbbVie’s menstrual-migraine study meets its primary and all ranked secondary goals
AbbVie ($ABBV) reported positive Phase 3 LUNA results for atogepant in menstrual migraine. The study enrolled 468 women and evaluated treatment across three menstrual cycles. Migraine days during the assessed menstrual period fell by 1.20 d ...
